Knee Osteoarthritis Articles & Analysis
18 news found
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete ...
ByEmovi
With the installation of three KneeKG Systems, the project will demonstrate the functionalities and performance of Emovi’s AI Platform combined with its KneeKG technology to the military health system. “Knee pain affects one person out of five and includes sports injuries and structural diseases such as knee osteoarthritis ...
ByEmovi
KneeKGTM is the first in-clinic device that enables healthcare professionals to accurately, objectively, and in real-time assess a patient’s knee(s) in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to pain ...
ByEmovi
” The NUsurface Meniscus Implant is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation. ...
“There is a significant need for new treatment options for patients who have persistent knee pain following a meniscectomy, which the NUsurface Implant may ...
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, ...
The technique is described as a Knee Kinesiography exam. “Knee pain is one of the most common complaints that physicians hear from patients,” says Dr. ...
ByEmovi
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with ...
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
“Injuries due to sports like anterior cruciate ligaments (ACL) injury, meniscus injury, and sciatic nerve injury can take an athlete out of the game they love and lead to knee osteoarthritis later in life – one of most common causes of disability.” Continued Laflamme, “Through all of our studies, we have seen how a Knee ...
ByEmovi
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...
Developed by Emovi, the KneeKGTM is to the knee, what an EKG is for the heart, and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is the second leading cause of chronic pain. A knee pain ...
ByEmovi
All of Intecore’s Physical Therapy locations – Aliso Viejo, CA; Foothill Ranch, CA; Orange, CA; San Juan Capistrano, CA and Bremerton, WA – will launch the KneeKG™ in their clinics this week. Knee pain is the second leading cause of chronic pain. One out of five people experiences knee pain during their life due to an injury or pathology ...
ByEmovi
Developed by Emovi, the KneeKG is for the knee, like an EKG is for the heart and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is the second leading cause of chronic pain. One out of five people experiences ...
ByEmovi
Further gel based products currently in development are designed to improve patients suffering from osteoarthritis in small joints and knee joint by simple non-surgical ...
This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: chronic low back pain, small joints osteoarthritis and knee osteoarthritis, and to enable Gelmetix to reach a wider audience, through a new website, videos and social media accounts, as we move closer to clinical ...
Hayward, CA, USA, March 15, 2017 – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS ...
Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma. About Osteoarthritis Osteoarthritis is one of the most common chronic health conditions and a leading cause of pain and disability among adults. Global estimates reveal that more than 100 million people are ...